Melbourne, Australia; 15 November 2011: Global regenerative medicine company, Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY), will host an investor conference call and webcast on Tuesday 15 November 8:15am Australian EDT (Monday, 14 November 2011 at 4:15pm U.S. EST, 9:15pm UK) following the presentation of data from its congestive heart failure clinical trial from 9:15am to 9:25am U.S. EST at the American Heart Association (AHA) Scientific Sessions 2011 in Orlando, Florida.
Professor Silviu Itescu, Mesoblast Chief Executive, will be joined on the call by Dr. Emerson Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute and lead investigator on the Phase 2 trial. The conference call will cover Mesoblast’s broad-based cardiovascular franchise as well as the results presented for its off-the-shelf adult stem cell product, Revascor™, in a presentation titled “A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients with Ischemic and Nonischemic Heart Failure” during the Clinical Science: Special Reports I session.
To participate in the conference call, please use the following dial-in information:
Australia Toll Free: 1 800 002 971
United States Toll Free: 1 866 711 8198
United Kingdom Toll Free: 08 08 234 7616
International Metered: + 1 617 597 5327 (if your location is not listed above)
Participant Code: 19449652
To access the live audio webcast of the presentation, or view an archived version of the webcast after the event, you may use the link: www.media-server.com/m/p/z4d2v52d. The archive will be available for 1 year on the company’s website – www.mesoblast.com
About Mesoblast
Mesoblast Limited (ASX: MSB) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).
For further information, please contact:
Julie Meldrum
Corporate Communications
Mesoblast Limited
T: + 61 (0) 3 9639 6036 or + 1 917 705 4030
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
For media enquiries in Europe, please contact:
Melanie Toyne Sewell/Daniel Gooch/Gemma Howe
College Hill Life Sciences
T: +44 (0)20 7866 7860
E: mesoblast@collegehill.com
